Expanded use of luspatercept for anaemiaMay 9, 2020
The FDA has cleared luspatercept (Reblozyl) for anaemia in adults with lower-risk MDS with ring sideroblasts – an uncommon form of the cancer characterised by red blood cell with iron-packed mitochondria that form a ring around the nucleus.
The approval is for use of the drug in patients who have failed standard red blood cell-boosting therapy with erythropoiesis stimulating agent (ESA) drugs like erythropoietin, and have needed transfusions of at least two units of red blood cells over the prior eight weeks.
Luspatercept got the approval from the FDA last November for anaemia in patients with beta thalassaemia who require regular blood transfusions, becoming the first erythroid maturation agent to be cleared by the regulator. It is also under regulatory review in Europe for this indication.